


# GASTRIC REFLUX




## causes heartburn

Reflux of gastric acid, which inflames and eventually erodes the delicate oesophageal mucosa, frequently gives rise to burning chest pain—described by the patient as 'heartburn'—a symptom which heralds more serious trouble unless it is dealt with promptly and thoroughly.




### Heartburn in:

Gastric reflux  
Reflux oesophagitis  
Hiatus hernia  
Pregnancy



# GAVISCON REFLUX



## prevents heartburn

1 By forming a viscous demulcent gel which floats as a 'raft' over the stomach contents Gaviscon physically suppresses gastric reflux.

2 When reflux becomes particularly vigorous the Gaviscon 'raft' itself is the first fraction to enter the oesophagus where it presents a unique physical barrier to acid attack—even when the patient stoops or lies down.

3 By thus soothing and protecting the delicate mucosa Gaviscon prevents pain, permits regression of inflammation and allows the irritated cardiac 'sphincter' to resume its normal competence.

4 A double-blind trial in patients with sliding hiatus hernia showed that Gaviscon produced almost total relief of regurgitation and heartburn in 79% and 67% of the patients respectively.\*


# GAVISCON<sup>Regd</sup>

## GASTRIC REFLUX SUPPRESSANT

Gaviscon contains: Alginate Acid BPC, Sodium Alginate BPC, Magnesium Trisilicate BP, Dried Aluminium Hydroxide Gel BP, Sodium Bicarbonate BP, Sucrose BP and Mannitol BP. Gaviscon is available as mint flavoured tablets and chocolate flavoured granules.

\*Current Medical Research and Opinion, (1972) 1, 63.

inside  
every Baritop can  
are fine radiographs  
waiting  
to get out



The excellent fluidity and optimum concentration of Baritop 100 form a unique combination of properties which results in superior visualisation of mucosal detail. Carbon dioxide is incorporated as an effervescent agent to aid double-contrast procedures and enhance the exceptional palatability of the suspension.

Baritop 100 is the modern liquid barium specifically formulated to match the sophistication of present day equipment and techniques.

The elegant barium suspension at 100% w/v in convenient 300ml cans.

**Low viscosity  
High density  
Carbonated  
barium  
Baritop 100**

**world's finest micronised  
barium suspension  
from Japan**

Further information available  
on request from

Concept Pharmaceuticals Limited  
Rickmansworth WD3 1EZ

Baritop is a registered trade mark

# **colofac<sup>®</sup>**

**is an antispasmodic  
that is not related  
to atropine**

**Name another!**

In the treatment of *the irritable colon syndrome* Colofac acts directly and selectively on colonic smooth muscle in spasm. Unlike the anticholinergic antispasmodics the action of Colofac is independent of the autonomic nervous system. Consequently Colofac relieves abdominal pain, discomfort after meals and disordered bowel function without causing the typical atropine-like side-effects of dry mouth, blurred vision and drowsiness. Each tablet of Colofac contains 100 mg. Mebeverine. Further information is available on request.

**colofac—the direct-acting antispasmodic**

mebeverine

**duphar** DUPHAR LABORATORIES LIMITED WEST END SOUTHAMPTON TEL 04218 2281  
PHILIPS DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271 

# The single solution

for parenteral nutrition


## Aminoplex 5

1 litre three times per day  
provides 15g. of utilisable  
nitrogen and 3000K calories;  
the nutrient content being  
derived from synthetic  
L-Form amino acids,  
sorbitol and alcohol.


### Geistlich Chester

*In co-operation with Salvia-Werk  
G.m.b.H., Homburg/Saar, W.Germany.*

Medical literature  
available from:  
**Geistlich Sons Ltd.,**  
Newton Bank,  
Long Lane,  
Chester CH2 3QZ.  
Telephone  
Chester 47534-7



Endoscopic Divisions of Human Body and Applicable Olympus Endoscopic Instruments



Any section of our endoscopy service  
will stand up to microscopic examination

KEYMED boasts the most  
comprehensive fund of expertise  
in fiberoptic endoscopy.

Olympus instruments: Olympus, world leaders in  
fiberoptic endoscopes—cover more specialties than  
any other, with the finest instruments.

The first—and only range of accessories designed specifically  
for endoscopists—the endoscopy trolley, cleaning unit,  
security storage cupboard, etc. all by Keymed.

KEYMED the specialist service for endoscopy equipment.

**KEYMED**

specialised medical equipment limited  
KeyMed House Stock Road Southend on Sea SS2 5HQ

Further information can be simply obtained by using the  
KEYMED Free Post Information Service,  
addressing envelope without postage to:  
Keymed Free Post Southend-on-Sea SS2 4BR.



# CAVED-S TABLETS

## SOME TRIAL SUMMARIES

### GUT 1968-9 48-51

#### SUMMARY

In a double blind clinical trial in which 54 patients\* were included, the effect of deglycyrrhizinized liquorice was investigated. Duodenal ulcer cases showed marked symptomatic improvement, with radiological healing demonstrable in a few cases.

\*48 Duodenal ulcer patients: 6 gastric ulcer patients.

Further confirmation of the activity of the drug was obtained from the treatment of six cases of gastric ulcer all of which showed extensive healing. Radiology demonstrated that the effect of the drug was spasmolytic in all duodenal ulcer patients, and that the side-effects were minimal. The great advantage of the treatment is that patients can be treated as ambulant and with a minimum loss of work.

### GUT 1971-72 449-451

#### SUMMARY

In our study no significant differences were found between the placebo and the treated groups.

The differences between the reported results are not easy to explain. Crossover trials in patients with duodenal ulcer are not easy to evaluate. In particular, it is not clear how after one month of reportedly successful therapy with complete relief of symptoms another drug (placebo) can be evaluated using clinical criteria. Even if the placebo is used first, the attack may be expected to subside within a month in part of the group.

In view of the conflicting reports more studies will have to be performed before a therapeutic effect can be attributed to deglycyrrhizinized liquorice in patients with duodenal ulcer.

It is not clear whether our results reflect on the efficacy of liquorice extract after the removal of carbenoxolone or merely on its efficacy in duodenal as contrasted to gastric ulcer. In common with others we found no side effects attributable to treatment with deglycyrrhizinized liquorice.

### GUT 10 299-302 1969

#### SUMMARY

In a double-blind clinical trial of deglycyrrhizinized liquorice 16 patients with gastric ulcer received the active drug for four weeks in a dose of 760 mg thrice daily and 17 the placebo. All patients, except four from each group who remained ambulant, were treated as outpatients. The results of the trial were assessed by the change in the size of the ulcer crater on barium meal before and after treatment.

Of the patients given the active drug, on average the size of the ulcer niche was reduced by 78%; in six patients (44%) the crater disappeared radiologically. In contrast the average reduction in size of the ulcer niche of the placebo group was 34% and in only one (6%) did the ulcer disappear. The difference in the reduction in ulcer size in favour of the treated group compared with the control group is statistically significant ( $P < 0.001$ ). None of the patients developed oedema and there was no excessive weight gain.


A pilot trial using Caved-(S) in a dose containing 760 mg of deglycyrrhizinized liquorice thrice daily for one month showed no toxic effects on fluid and electrolyte balance in 10 patients.

Protective Action of Deglycyrrhizinized Liquorice on the Occurrence of Stomach Ulcers in Pylorus-Ligated Rats. *Scand. J. Gastroent.*, 6, 683-686.

The effect of graded doses of a deglycyrrhizinized liquorice extract (d.Li.) was studied on the frequency of stomach ulcers and the secretion of gastric juice in pylorus-ligated rats. 25-50 mg of d.Li. given intraperitoneally reduced considerably the number of ulcers in comparison with the control group of rats without any significant changes in gastric secretion. Higher doses—100-200 mg—gave complete protection against the development of gastric ulcers and also reduced the output of gastric juice. The results give strong support for the existence of an ulcer-protecting principle in the d.Li.

*Key-words:* Gastric secretion; gastric ulcers; liquorice; pylorus-ligated rats.

*Dept. of Pharmacology, Karolinska institutet, S-104 01 Stockholm 60, Sweden.*



## Flatulent dyspepsia. And not for the first time.

Or the second, or the third. The patient probably has a history of repeated visits to her general practitioner, and a variety of treatments have failed to resolve the cause of her symptoms.

After investigation, you will wish to establish a treatment that will take account of the underlying problem. In such a patient this is likely to be a disturbance in gastroduodenal motility. Maxolon restores normal gastro-

duodenal motility, and clinical experience confirms that 4 out of 5 patients with dyspeptic symptoms benefit from treatment with Maxolon.

*Full information on the use of Maxolon in hospitals is available on request.*

Maxolon\* (metoclopramide) is a product of



**Beecham Research  
Laboratories**  
Brentford, England

\*regd.



## **Maxolon** for flatulent dyspepsia.

---

# Nutrizym®

---

**unique two-stage replacement or supplemental therapy  
in pancreatic insufficiency**

*Extensive clinical evidence\* indicates that Nutrizym is significantly more effective than its competitors in improving fat absorption and protein digestion, and in reducing faecal weight.*

Each Nutrizym tablet has an enteric-coated pancreatic core and a shell of bromelains – proteolytic enzymes of the pineapple – which are active within the pH range of pH3 and pH8 (even pH2 for short periods) and therefore act without loss of enzymatic effectiveness at the low pH found in the stomach.

Following ingestion of the tablet, the bromelains are liberated in the stomach, where proteolytic action is required, and pancreatin is released in the duodenum. Additionally, the bromelains aid digestion in the small intestine where they develop their full proteolytic effect.

Nutrizym is indicated in: pancreatic deficiency states including post-gastrectomy malabsorption, fibrocystic and gastro-intestinal disorders resulting in steatorrhoea.

Nutrizym: each tablet contains Bromelains 50mg. Pancreatin \*\* 4 x N.F. 400mg, and Ox bile 30mg.

\*\* activity equivalent to four times pancreatin B.P.

Dosage: 1 tablet to be taken with meals. Further tablets may be taken according to the degree of pancreatic exocrine insufficiency.

*Full information on request*

---

**E. Merck Limited, Wokingham, Berks.**

---

\*Brit.med.J., 1970, 4, 21    Medical Digest, 1972, 17, 54    Gastroenterologie 1969, 7, 314.

---



# duphalac<sup>®</sup> in lactulose liver failure

*Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut\* describes its role in these terms.*

"Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .  
... lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required". \*Gut, 1970, 11: 1043-1048

***The following work on Duphalac in portal systemic encephalopathy has been published:***

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1: 890-892

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2: 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2: 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76: 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11: 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281: 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18: 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose  
*Therapeutische Umschau und medizinische Bibliographie*, 1969, 26: 275-277

Lactulose treatment of chronic hepatportal encephalopathy: a clinical and electroencephalographic study  
*Acta medica Scandinavica*, 1970, 187: 337-346


The value of EEG frequency analysis in hepatic encephalopathy  
*J. Ryl. Coll. Surg. Edinb.*, 1970, 15: 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy  
*Quarterly Journal of Medicine*, 1970, 39: 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy  
*Gastroenterology*, 1970, 59: 827-832

**Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.**

Further information available on request.



# GEFARNIL

## the systemic treatment for peptic ulcers

Gefarnil is unique. Its action is systemic. Gefarnil treats peptic ulcer by acting on the ulcer via the blood stream. Its action is quite specific. By repairing the tissue damage of gastric and duodenal ulceration, Gefarnil heals the ulcer.



Gefarnil is gefarnate in capsules of 50 mg. Gefarnil is manufactured under licence from Istituto de Angeli SpA, Milan, Italy by The Crookes Laboratories Ltd., Basingstoke, Hants, from whom full information is available.

P3629

# GASTROENTEROLOGY:

---

## The monthly seminar

You may object to our calling a medical journal a seminar. But consider it this way: each month, you share in the results of research and clinical studies of your confreres. When the after-hours free you at the end of the day's appointments, consult GASTROENTEROLOGY. You'll find:

- 1.) **Selected summaries.** Abstracts of relevant new work, with a brief expert critique.
- 2.) **Original papers.** Studies of the liver, alimentary tract, pancreas and biliary tract.
- 3.) **Case Studies.** Dealing with clinical research.

Too, there'll be editorials, symposium reports, and a "special comments" section for readers to present their views of papers that have appeared in recent issues—your chance to participate in the "monthly seminar" when you so desire.

**GASTROENTEROLOGY.** The official organ of the American Gastroenterological Association. From the Williams and Wilkins Company.

Published monthly/2 volumes per year/Subscription: \$25 (Resident rate: \$15.00)  
Overseas postage: \$3.00

### Sample Selections

**Presentation of the Julius Friedenwald Medal to Andrew Conway Ivy.**  
*M. I. Grossman*

**Effect of Long Term Anticholinergic Therapy on Gastric Acid Secretion, with Observations on the Serial Measurement of Peak Histalog Response.**  
*R. P. Norgaard, D. E. Polter, J. W. Wheeler, Jr., and J. S. Fordtran.*

**A Controlled Study on the Use of Propantheline and Amylopectin Sulfate (SN-263) for Recurrences in Duodenal Ulcer.** *D. C. H. Sun and M. L. Ryan.*

**Basal and Histamine-stimulated Human Gastric Acid Secretion. Lack of Effect of Indomethacin in Therapeutic Doses.** *D. H. Winship and G. C. Bernhard.*

**Gastric Juice Lactic Acidosis in the Presence of Gastric Carcinoma.** *D. W. Piper, M. L. Kemp, B. H. Fenton, M. J. Croydon, and A. D. Clarke.*

Published by **The Williams & Wilkins Company, Baltimore, Maryland, U.S.A.**

Sole agent in England: **Bailliere, Tindall & Cassell Ltd., 7 & 8 Henrietta Street, Covent Garden, London, W.C.2**

# SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Volume 7, No. 8, 1972

## CONTENTS

Review: K. Winkler: <i>Selection of Patients with Cirrhosis of the Liver for Shunt Surgery</i> .. ..	679
E. Schrumpf & T. Sand: <i>Radioimmunoassay of Gastrin with Activated Charcoal</i> .. ..	683
N. G. Kock, J. Kewenter & T. Sundin: <i>Studies of the Defecation Reflex in Man</i> .. ..	689
O. Hart Hansen, O. Kronberg & T. Pedersen: <i>The Double Pylorus</i> .. ..	695
CH. Bode, O. Zelder, H. Goebell & H.-O. Neuberger: <i>Choleresis Induced by Secretin: Distinctly Increased Response in Cirrhotics</i> .. ..	697
H. Dencker, A. Lunderquist, G. Meeuwisse, C. Norrby & K.-G. Tranberg: <i>Absorption of Fructose as Measured by Portal Catheterization</i> .. ..	701
H. Dencker, E. Johanneson, G. Meeuwisse, C. Norrby & K.-G. Tranberg: <i>Absorption of Maltose as Measured by Portal Catheterization</i> .. ..	707
R. Capoferro: <i>Intestinal Metaplasia in Experimental Atrophic Gastritis</i> .. ..	711
S. Aune & J. O. Stadaas: <i>The Inhibitory Effect of Sulpiride on Pentagastrin-Stimulated Gastric Secretion</i> .. ..	713
J. O. Stadaas & S. Aune: <i>The Effect of Sulpiride on Gastric Motility</i> .. ..	717
F. Boberg, T. Hattel, O. E. Nielson & The Copenhagen Study Group for Liver Diseases: <i>The Effect of Prednisone on Serum Cholesterol in Patients with Cirrhosis of the Liver</i> .. ..	723
S. Lenninger & T. Olin: <i>The Effect of Methacholine on the Pancreatic Duct of the Cat Studied with a Radiological Method</i> .. ..	727
E. Hansen & E. S. J. Rune: <i>Effect of Chewing Gum on Gastric Acid Secretion</i> .. ..	733
G. Goldstein & S. P. Mistilis: <i>Active Chronic Hepatitis: Use of Bromosulphthalein Tm and S in Estimating Disease Activity</i> .. ..	737
H. J. Fenger, E. Gudmand-Hoyer & K. Rasmussen: <i>A Modification of the Apomorphine Dumping Test</i> .. ..	743
N. P. Boye, A. Nordoy & E. Gjone: <i>Splenectomy in Active Chronic Hepatitis</i> .. ..	747
S. Emas & S.-O. Svensson: <i>Dose-Response Curves for Acid Output to Histamine and Pentagastrin Determined by Two Techniques</i> .. ..	751

Issued 30 November 1972

THE SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY publishes original papers in gastroenterology and pertinent fields of nutrition. Each issue contains about 100 pages; eight issues form one annual volume. Supplements are supplied free of charge to subscribers. The subscription price, including postage, is N. kr. 220.-(U.S. \$36.-) payable in advance.

### *Editorial Correspondence*

Manuscripts should be addressed to the managing editor. The Scandinavian Journal of Gastroenterology has no objection to the reproduction of short passages and illustrations from this journal without further formality than acknowledgement of the source.

### *Business Communications*

Business communications, including subscriptions and orders for reprints or advertisements, should be sent to the publishers.

Publishers  
UNIVERSITETSFORLAGET  
P.O. Box 307, Blindern, Oslo 3 Norway